Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos, Exelixis Pen Gene Function Partnership

NEW YORK, Jan. 23 - Galapagos Genomics and Exelixis have penned an agreement under which Exelixis will use Galapagos' adenoviral technology to analyze gene function in cell-based assays.

 

Galapagos, a functional genomics company based in Belgium, will reconstruct recombinant adenoviruses that include genes selected by Exelixis. Researchers at Exelixis will then introduce the vectors into a range of cell types in order to evaluate protein function of the selected genes in disease-relevant pathways.

 

Financial details of the deal were not disclosed.

 

Galapagos' technology can be used to link genes with a range of phenotypic characteristics like morphology, motility, proliferation, differentiation and signal transduction.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.